Transactie bevordert KD Pharma’s cannabinoïde productiestrategie

BIOGGIO, Zwitserland-(BUSINESS WIRE)- De KD Pharma Group heeft de productieactiva verworven van een in Zwitserland gevestigde fabrikant van cannabinoïden. De activa geven KD Pharma toegang tot technologie voor de productie van Active Pharmaceutical Ingredients (API’s) op basis van fytocannabinoïden en andere plantenextracten. De technologie breidt KD’s portfolio van lipidentechnologie verder uit en kan worden gebruikt in combinatie met KD’s andere fractionerings- en scheidingstechnologieën.

“KD Pharma is een leider in lipidentechnologie die zich voornamelijk richt op omega-3s, maar onze technologie suite heeft toepassingen in andere lipide bronnen zoals cannabinoïden,” zegt Oscar Groet, CEO van de KD Pharma Group. “We hebben ons geëngageerd om onze technologieportfolio uit te breiden om API’s te ontwikkelen op basis van cannabinoïden en plantenextracten,” vervolgde Groet, “en deze activa geven KD Pharma bijkomende paden om nieuwe producten te ontwikkelen voor deze opkomende markt.”

KD Pharma Acquires Phytoextract and CBD Manufacturing Assets

Transaction advances KD Pharma’s cannabinoid manufacturing strategy

BIOGGIO, Switzerland–(BUSINESS WIRE)– The KD Pharma Group has acquired the manufacturing assets of a Swiss-based cannabinoid manufacturer. The assets give KD Pharma access to technology for producing Active Pharmaceutical Ingredients (APIs) based on phytocannabinoids and other plant extracts. The technology further expands KD’s lipid technology portfolio and can be used in combination with KD’s other fractionation and separation technologies.

“KD Pharma is a leader in lipid technology focused primarily on omega-3s, but our technology suite has applications in other lipid sources like cannabinoids,” said Oscar Groet, CEO of the KD Pharma Group. “We have committed to expanding our technology portfolio to develop APIs from cannabinoids and plant extracts,” Groet continued, “and these assets give KD Pharma additional pathways to develop new products for this emerging market.”

The KD Pharma Group has also licensed a novel extraction method from Herbolea Biotech S.r.l. and expects to have a complete, licensed cGMP manufacturing facility online by the end of the year.

About the KD Pharma Group

The KD Pharma Group is a contract manufacturer that develops products in the pharmaceutical and nutraceutical space. It is also one of the largest Omega-3 fatty acid producers in the world with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents. Visit www.kdpharmagroup.com to learn more.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005035/en/

Contacts

Adam Ismail

Chief Strategy Officer

KD Pharma Group

+1 (385) 237-2787

adam.ismail@kdpharmagroup.com